A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/25/2009	EP2121957A1 Macrolactams by engineered biosynthesis
11/25/2009	EP2121926A1 Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
11/25/2009	EP2121769A1 Low molecular weight heparins including at least one covalent bond with biotin or a biotin derivative, method for making same and use thereof
11/25/2009	EP2121767A1 Process methods for fucoidan purification from seaweed extracts
11/25/2009	EP2121723A2 Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents
11/25/2009	EP2121722A2 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof
11/25/2009	EP2121719A2 2-5a derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
11/25/2009	EP2121717A2 Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
11/25/2009	EP2121716A1 Compositions of stable tiacumicins
11/25/2009	EP2121715A1 Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
11/25/2009	EP2121714A1 Aminoglycoside antibiotics targeting bacterial 16s ribosomal rna
11/25/2009	EP2121711A1 Carborane-phosphonium compounds and their use in boron neutron capture therapy and imaging
11/25/2009	EP2121705A2 A2a adenosine receptor antagonists
11/25/2009	EP2121704A2 Polymorphic forms of clopidogrel hydrobromide
11/25/2009	EP2121700A1 Substituted tetrahydroquinolines
11/25/2009	EP2121697A1 Compounds for the treatment of hepatitis c
11/25/2009	EP2121686A1 Indolizineacetic acids and their therapeutic use as ligands of the crth2 receptor
11/25/2009	EP2121683A2 2- piperazin-1-yl-3h-imidazo[4,5-b]pyridine derivatives
11/25/2009	EP2121681A1 Compounds and method for treatment of cancer
11/25/2009	EP2121676A1 Preperation and utility of ccr5 inhibitors
11/25/2009	EP2121672A2 Substituted gamma lactams as therapeutic agents
11/25/2009	EP2121668A2 6,8-dichlorchroman-3-yl-1,3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
11/25/2009	EP2121659A1 Modulators of cb1 receptors
11/25/2009	EP2121658A2 Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same
11/25/2009	EP2121657A1 Sulfonylated heterocycles useful for modulation of the progesterone receptor
11/25/2009	EP2121655A1 Novel 2-heteroaryl substituted indoles 695
11/25/2009	EP2121652A1 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
11/25/2009	EP2121650A1 Isoflavone derivatives and uses thereof
11/25/2009	EP2121640A1 Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
11/25/2009	EP2121637A1 Anthranilamide inhibitors of aurora kinase
11/25/2009	EP2121634A1 Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors
11/25/2009	EP2121630A1 Fast dissociating dopamine 2 receptor antagonists
11/25/2009	EP2121627A1 Benzimidazole derivatives
11/25/2009	EP2121626A1 Benzimidazole derivatives
11/25/2009	EP2121625A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121624A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121623A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121622A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121621A1 Lxr and fxr modulators
11/25/2009	EP2121617A1 Cb1 receptor modulators
11/25/2009	EP2121614A1 Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors
11/25/2009	EP2121608A1 Dihydropyridine derivatives useful as protein kinase inhibitors
11/25/2009	EP2121606A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121602A1 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
11/25/2009	EP2121600A2 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions
11/25/2009	EP2121599A2 Nitroxides for use in treating or preventing hypercholesterolemia
11/25/2009	EP2121596A1 Atorvastatin strontium salt and pharmaceutical composition comprising same
11/25/2009	EP2121594A1 Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
11/25/2009	EP2121591A2 Ppar active compounds
11/25/2009	EP2121590A2 Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
11/25/2009	EP2121586A2 Regulation of osteopontin
11/25/2009	EP2121585A1 Novel aminoguanidines as melanocortin receptor ligands.
11/25/2009	EP2121582A1 Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form
11/25/2009	EP2121579A1 Malonamides as orexin antagonists
11/25/2009	EP2121576A1 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
11/25/2009	EP2121575A2 Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
11/25/2009	EP2121572A2 Preparation and utility of substituted allylamines
11/25/2009	EP2121139A1 Formulations for cancer treatment
11/25/2009	EP2121057A1 Polymerization with precipitation of proteins for elution in physiological solution
11/25/2009	EP2121025A2 Methods and compositions for the delivery of a therapeutic agent
11/25/2009	EP2121024A2 Stabilization of vitamin b12
11/25/2009	EP2121001A2 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
11/25/2009	EP2120998A2 Modified erythropoietin polypeptides and uses thereof for treatment
11/25/2009	EP2120995A2 The secreted protein ccdc80 regulates adipocyte differentiation
11/25/2009	EP2120990A1 Reducing post-operative adhesion formation with intraperitoneal glutamine
11/25/2009	EP2120974A1 Self-assembling amphiphilic polymers as antiviral agents
11/25/2009	EP2120973A1 Modulation of proteases. particularly in the treatment of chronic ulcerous skin lesions
11/25/2009	EP2120972A1 Amido-amine polymer compositions
11/25/2009	EP2120971A1 Imidated biopolymer adhesive and hydrogel
11/25/2009	EP2120970A1 Heparins including at least one covalent bond with biotin or a biotin derivative, method for preparing same and use thereof
11/25/2009	EP2120969A1 Stabilized sulforaphane
11/25/2009	EP2120968A1 Use of d-ribose to treat cardiac arrhythmias
11/25/2009	EP2120967A1 Method for promoting wound healing
11/25/2009	EP2120966A2 Polymeric short interfering rna conjugates
11/25/2009	EP2120963A2 Substituted tetracycline compounds for treatment of inflammatory skin disorders
11/25/2009	EP2120962A1 Methods and compositions for treating gastrointestinal disorders
11/25/2009	EP2120961A1 Treprostinil treatment for interstitial lung disease and asthma
11/25/2009	EP2120960A2 NOVEL ß-LACTAM ANTIBIOTICS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF
11/25/2009	EP2120958A2 Stat3 inhibitor having anti-cancer activity and associated methods
11/25/2009	EP2120957A1 Compounds and uses thereof
11/25/2009	EP2120955A1 Pellets comprising an active substance matrix and a polymer coating, and a method for producing said pellets
11/25/2009	EP2120954A1 Adenosine derivatives as partial and full agonists of a1 adenosine receptors
11/25/2009	EP2120952A2 Antiviral compounds and methods of using thereof
11/25/2009	EP2120951A1 Inhibitors of akt activity
11/25/2009	EP2120950A1 Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
11/25/2009	EP2120949A1 Use of flibanserin for the treatment of insomnia
11/25/2009	EP2120948A1 Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
11/25/2009	EP2120947A1 Use of nicotinamide for treatment and/or prevention of arteriosclerosis
11/25/2009	EP2120946A1 Pharmaceutical composition comprising nicotinamide or nicotinic acid
11/25/2009	EP2120943A2 Nitroxide radical as a treatment for neurodegeneration
11/25/2009	EP2120939A2 Substituted pyridine n-oxide herbicides
11/25/2009	EP2120938A1 Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
11/25/2009	EP2120937A1 A composition comprising (r)-spiro[l- azabicyclo[2.2.2]octane-3,2'(3'h) -furo[2,3 -b]pyridine (azd0328) and its use in the treatment of alzheimer's disease, adhd or cognitive dysfunction
11/25/2009	EP2120936A1 Novel methods
11/25/2009	EP2120935A1 Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
11/25/2009	EP2120932A1 Indazole derivatives as kinase inhibitors for the treatment of cancer
11/25/2009	EP2120930A1 Use of chromium histidinate for treatment of cardiometabolic disorders
11/25/2009	EP2120929A1 Use of inhibitors of the degradation of p27, in particular argyrin and derivatives thereof, for the treatment of proliferative diseases
11/25/2009	EP2120927A1 Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
11/25/2009	EP2120926A1 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

1 ... 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 ... 7860